Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IMNM

IMNM - Immunome Inc Stock Price, Fair Value and News

$20.37-0.62 (-2.95%)
Market Closed

17/100

IMNM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

17/100

IMNM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IMNM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMNM Price Action

Last 7 days

-3.2%

Last 30 days

-13.0%

Last 90 days

4.1%

Trailing 12 Months

128.1%

IMNM RSI Chart

IMNM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMNM Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-10.85

Price/Sales (Trailing)

332.02

Price/Free Cashflow

-11.49

IMNM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IMNM Fundamentals

IMNM Revenue

Revenue (TTM)

6.9M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

IMNM Earnings

Earnings (TTM)

-212.4M

Earnings Growth (Yr)

12.9%

Earnings Growth (Qtr)

-21.66%

IMNM Profitability

Return on Equity

-33.48%

Return on Assets

-31.09%

Free Cashflow Yield

-8.7%

IMNM Investor Care

Shares Dilution (1Y)

30.11%

Diluted EPS (TTM)

-2.42

IMNM Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202510.9M12.6M9.7M6.9M
202412.7M10.8M10.1M9.0M
20234.0M7.3M10.7M14.0M
2022000622.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Immunome Inc

IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
 CEO
 WEBSITEhttps://immunome.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES37

Immunome Inc Frequently Asked Questions

IMNM is the stock ticker symbol of Immunome Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Immunome Inc is 2.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, IMNM's PE ratio (Price to Earnings) is -10.85 and Price to Sales (PS) ratio is 332.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMNM PE ratio will change depending on the future growth rate expectations of investors.